Table 1.

Treatment regimens and outcomes for all patients with rifampicin mono‐resistant TB who underwent treatment in Queensland, Australia.

Age (years)/gender	HIV status	Site of disease	Smear status	Cavitary disease	Treatment Regimen	Total duration (months)	Outcome*
35/male	Negative	Extrapulmonary (lymph node)	Negative	—	2 HRZE, 13 HE	15	Treatment completed
33/female	Negative	Extrapulmonary (lymph node)	Negative	—	2 HRE, 10 HZE	12	Treatment completed
34/female	Negative	Extrapulmonary (gastrointestinal)	Negative	—	19 HZE	19	Treatment completed
33/male	Negative	Pulmonary	Negative	Yes	1 HRZE, 3Mfx HZE, 1Mfx HE, 13 Mfx H	18	Treatment completed
26/male	Negative	Pulmonary	Negative	Yes	2 HRZE, 12 Mfx HZE	14	Treatment completed
32/male	Negative	Pulmonary	Positive	Yes	1 Mfx HZE, 11 Mfx HE	12	Treatment success
20/female	Negative	Pulmonary	Positive	Yes	2 Amk Mfx HZE, 5 Mfx HZE, 5 HZE	12	Treatment success

Amk, amikacin; E, ethambutol; H, isoniazid; Mfx, moxifloxacin; R, rifampicin; Z, pyrazinamide.

^* Outcomes defined by WHO for rifampicin‐resistant TB 10.